KYMR
Kymera Therapeutics, Inc.Company Information
- Company Name
- Kymera Therapeutics, Inc.
- CIK
- CIK0001815442
- Category
- Large accelerated filer
- Ticker: Exchange
- KYMR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- KYMR
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-11
- Last sale
- 2026-09-04
- Shares purchased (TTM)
- 2,005,813
- Shares sold (TTM)
- 3,614,782
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 83,945,334
- Shares outstanding
- 98,177,158
- Ownership
- 85.50%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 12.01%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 124 | 144 | 357 | 113 | 336 | 90 | 120 | 111 | 68 | 94 | 110 | 81 | ||||||
| Available For Sale Securities Debt Securities Current | 567 | 507 | 491 | 393 | 330 | 373 | 368 | 439 | 442 | 427 | 265 | 277 | ||||||
| Contract With Customer Asset Net Current | - | - | - | 0 | 0 | 20 | 1 | 1 | 2 | 2 | 4 | 4 | ||||||
| Accounts Receivable Net Current | 20 | - | - | - | 40 | - | 0 | 0 | 0 | 0 | 15 | - | ||||||
| Prepaid Expense And Other Assets Current | 26 | 27 | 23 | 23 | 23 | 18 | 22 | 17 | 14 | 15 | 12 | 14 | ||||||
| Assets Current | 737 | 677 | 871 | 528 | 728 | 501 | 510 | 569 | 525 | 537 | 405 | 376 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 814 | 895 | 771 | 473 | 298 | 312 | 362 | 361 | 192 | 224 | 61 | 77 | ||||||
| Property Plant And Equipment Net | 40 | 42 | 43 | 45 | 49 | 49 | 50 | 51 | 52 | 49 | 48 | 36 | ||||||
| Operating Lease Right Of Use Asset | 41 | 42 | 42 | 43 | 46 | 47 | 47 | 48 | 49 | 49 | 53 | 55 | ||||||
| Other Assets Noncurrent | 7 | 8 | 9 | 7 | 5 | 3 | 2 | 0 | 2 | 2 | 2 | 3 | ||||||
| Restricted Cash Noncurrent | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | ||||||
| Assets | 1,645 | 1,669 | 1,743 | 1,102 | 1,131 | 918 | 978 | 1,035 | 826 | 868 | 576 | 552 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 9 | 13 | 4 | 6 | 6 | 10 | 6 | 6 | 7 | 7 | 7 | 5 | ||||||
| Accrued Liabilities Current | 48 | 35 | 42 | 29 | 28 | 23 | 35 | 27 | 24 | 16 | 34 | 26 | ||||||
| Contract With Customer Liability Current | 0 | 0 | 23 | 23 | 40 | 11 | 14 | 20 | 19 | 23 | 38 | 27 | ||||||
| Operating Lease Liability Current | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 11 | 9 | 5 | 3 | ||||||
| Finance Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Liabilities Current | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | ||||||
| Liabilities Current | 71 | 63 | 83 | 72 | 88 | 59 | 68 | 67 | 62 | 56 | 86 | 63 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Contract With Customer Liability Noncurrent | 0 | 0 | 11 | 14 | - | - | 0 | 0 | 3 | 24 | 17 | 16 | ||||||
| Operating Lease Liability Noncurrent | 64 | 66 | 67 | 68 | 70 | 71 | 72 | 74 | 75 | 76 | 77 | 77 | ||||||
| Finance Lease Liability Noncurrent | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 136 | 129 | 163 | 156 | 160 | 132 | 142 | 142 | 141 | 157 | 181 | 157 | ||||||
Stockholders Equity | ||||||||||||||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 2,713 | 2,679 | 2,644 | 1,924 | 1,868 | 1,606 | 1,592 | 1,575 | 1,308 | 1,292 | 926 | 914 | ||||||
| Retained Earnings Accumulated Deficit | -1,196 | -1,135 | -1,066 | -979 | -897 | -820 | -755 | -684 | -621 | -579 | -531 | -516 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -7 | -4 | 2 | 2 | 0 | -0 | -1 | 2 | -2 | -2 | -1 | -2 | ||||||
| Stockholders Equity | 1,509 | 1,540 | 1,580 | 946 | 971 | 786 | 836 | 893 | 685 | 711 | 395 | 396 | ||||||
| Liabilities And Stockholders Equity | 1,645 | 1,669 | 1,743 | 1,102 | 1,131 | 918 | 978 | 1,035 | 826 | 868 | 576 | 552 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - | - | - | - | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | - | 10 | - | - | - | - | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 83 | 82 | 81 | 72 | 71 | 65 | 65 | 65 | 62 | 61 | 56 | 55 | ||||||
| Shares Outstanding | 83 | 82 | 81 | 72 | 71 | 65 | 65 | 65 | 62 | 61 | 56 | 55 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKymera Therapeutics, Inc. (KYMR) — SEC Financial Statements & Analysis
Kymera Therapeutics, Inc. (KYMR) is a biological products, (no diagnostic substances) company, incorporated in DE. Kymera Therapeutics, Inc. trades on Nasdaq as: KYMR. Kymera Therapeutics, Inc. (KYMR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Kymera Therapeutics, Inc. carries a market cap of $11.26B, a P/E ratio of -37.58x, a P/B ratio of 7.46x, a P/S ratio of 107.22x, an enterprise value of $11.14B, and an EV/EBITDA multiple of -32.57x. On profitability, it posts an operating margin of -333.50%, a net margin of -285.33%, a Return on Equity (ROE) of -24.15%, a Return on Assets (ROA) of -21.58%, and a Return on Invested Capital (ROIC) of -34.50%. Per share, it reports EPS of $-3.05, diluted EPS of $-3.05, free cash flow per share of $-2.42, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 134.84% year-over-year, net income growth of 8.77% year-over-year, and EPS growth of -10.87% year-over-year. On the balance sheet, it maintains a current ratio of 10.34x, a quick ratio of 9.97x, working capital of $665.94M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.08, free cash flow of $-237.96M (TTM), and net debt of $-122.06M. Figures sourced from SEC EDGAR.
- Market Cap
- $11.26B
- P/E TTM
- -37.58x
- EPS TTM
- $-3.05
- P/B TTM
- 7.46x
- ROE TTM
- -24.15%
- ROA TTM
- -21.58%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-237.96M
- Net Revenue TTM Growth 1Y
- 134.84%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Kymera Therapeutics, Inc. in?
Kymera Therapeutics, Inc. (KYMR) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does KYMR trade on?
Kymera Therapeutics, Inc. (KYMR) trades on the Nasdaq.
Where is Kymera Therapeutics, Inc. incorporated?
Kymera Therapeutics, Inc. is incorporated in DE.
When was Kymera Therapeutics, Inc. (KYMR)'s most recent SEC filing?
Kymera Therapeutics, Inc. (KYMR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is KYMR's market cap?
Kymera Therapeutics, Inc. (KYMR) has a market capitalization of $11.26B as of 2026-06-30.
What is KYMR's EPS (earnings per share)?
Kymera Therapeutics, Inc. (KYMR)'s trailing twelve month EPS is $-3.05 as of 2026-06-30.
What is KYMR's ROE (return on equity)?
Kymera Therapeutics, Inc. (KYMR)'s trailing twelve month Return on Equity (ROE) is -24.15% as of 2026-06-30.
What is KYMR's ROA (return on assets)?
Kymera Therapeutics, Inc. (KYMR)'s trailing twelve month Return on Assets (ROA) is -21.58% as of 2026-06-30.
What is KYMR's ROIC (return on invested capital)?
Kymera Therapeutics, Inc. (KYMR)'s trailing twelve month Return on Invested Capital (ROIC) is -34.50% as of 2026-06-30.
What is KYMR's EV/EBITDA?
Kymera Therapeutics, Inc. (KYMR)'s trailing twelve month EV/EBITDA is -32.57x as of 2026-06-30.